dr. oh on remaining challenges with docetaxel in prostate cancer
Published 7 years ago • 229 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
0:46
dr. oh on challenges with developing novel targeted agents in prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:24
dr. higano on docetaxel for hormone-sensitive prostate cancer
-
2:17
dr. feldman on remaining challenges with biomarkers in prostate cancer
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:36
dr. oh on results of chemotherapy versus arta in prostate cancer
-
0:53
dr. oh on the sequencing of new therapies for prostate cancer
-
0:48
dr. kantoff on evolving role of docetaxel in prostate cancer treatment
-
1:56
dr. oh on targeted treatment in metastatic castration-resistant prostate cancer
-
1:15
dr. oh on the hormone-sensitive setting in prostate cancer
-
1:02
dr. oh discusses the role of chemotherapy in prostate cancer
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
2:07
dr. kantoff on docetaxel plus androgen deprivation therapy in prostate cancer
-
1:17
dr. hamid on a potential biomarker of response to docetaxel in mhspc
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
4:52
docetaxel in non-metastatic prostate cancer